Enrico De Toni
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients (NCT05844046) | Enrico De Toni | 2023-04-06 |
Track Enrico De Toni automatically
Every clearance here is in the API, with alerts when new ones post.